Developer docs
API playgroundTry for free, no card

Search company profiles

LifeSign

Full company profile

uuid002la49

Namestring
LifeSign
Legal namestring
LifeSign LLC
Websiteurl
lifesignmed.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

LifeSign LLC is a privately held medical diagnostic company founded in 1998 and headquartered at 85 Orchard Road, Skillman, New Jersey. The company manufactures rapid point-of-care (POC) lateral-flow immunoassay diagnostic tests and serves three core customer segments: healthcare providers (hospitals, clinics, physician offices, laboratories) requiring rapid disease detection and screening, industrial and manufacturing operators needing microbial contamination monitoring (paint, cutting fluids, paper/pulp, fuel tanks), and food service and institutional buyers conducting surface hygiene verification. Product brands include Status™ (rapid immunoassays for infectious disease, cardiac markers, drugs of abuse, women's health, GI health, urology, and alcohol/nicotine testing), Cultura® (incubators), Easicult® (industrial dip slides), Hygicult® (surface hygiene paddles), and Uricult® (in-office urine culture). The portfolio spans 10 product categories sold through direct phone ordering (800-526-2125) and online catalog channels at unit-level pay-as-you-go pricing with no subscription component.

The underlying technology is proprietary rapid immunoassay lateral-flow chemistry delivering visual read-out results typically within 5–15 minutes, with several assays carrying CLIA-waived status for use without complex laboratory infrastructure. Notable technical features include the Status COVID-19/Flu A&B combination assay (FDA Emergency Use Authorization, 93.9%/91.4%/87.6% sensitivity for SARS-CoV-2, Flu A and Flu B), Status MI Troponin I and the 3-in-1 CK-MB/Myoglobin/Troponin I panel for acute myocardial infarction work-up, Status DS drugs-of-abuse assays with 97–99% GC/MS correlation, Status hCG with reduced hook-effect susceptibility, and the Uricult in-office urine culture system (Moderately Complex CLIA, 24-hour culture). Companion hardware includes the Cultura M incubator for dip-paddle workflows. Performance and packaging documentation (package inserts, safety data sheets, sell sheets) are downloadable from the company website.

The commercial model is a focused direct-to-provider B2B motion targeting institutional buyers, with no disclosed distributor or platform dependency, no subscription revenue, and no public listing or external institutional investment. Brand visibility was supplemented in late 2025 via a corporate sponsorship of Major League Table Tennis (announced November 22, 2025) alongside co-sponsors First Advantage and Princeton BioMeditech, coinciding with MLTT's expansion to ten teams and a CBS Sports television deal. The firm operates with 11–50 employees, no disclosed management team, no disclosed certifications or accreditations, and an operating geography skewed to the United States with an aspirational 'global' claim. The broader diagnostic biomarkers market is sized to reach $155.92 billion by 2030 at a 15.5% CAGR, against which LifeSign's current scope is a small, narrowly-scaled participant.

Short descriptiontext

LifeSign LLC manufactures rapid point-of-care immunoassay diagnostic tests across 10 categories, including infectious disease, cardiac, women's health, urology, and drugs of abuse. Founded 1998 in Skillman, NJ, the privately held firm sells direct to healthcare, industrial, and food service customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSkillman, United States
HQ citystring
Skillman
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid diagnostic tests, point-of-care testing, immunoassay diagnostics, medical diagnostic devices, infectious disease testing
Industry3 codes
PRIMARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Point-of-Care Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Point-of-Care Diagnostic Tests
TypeOne Time License
Description

LifeSign generates revenue through the sale of rapid point-of-care diagnostic test kits to healthcare providers. Products include tests for infectious diseases, cardiac markers, drugs of abuse, women's health, GI health, urology, and industrial hygiene applications.

lifesignmed.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Status COVID-19/Flu A&B - 1 test device
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Status COVID-19/Flu A&B rapid immunoassay for simultaneous detection of SARS-CoV-2 and Influenza A/B

lifesignmed.com
2Status Nicotine - 35 tests
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Status DS Nicotine rapid immunoassay, results in 5-10 minutes, 500 ng/mL cut-off

lifesignmed.com
3Easicult TTC - 10 tests
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Easicult TTC dip slides for industrial microbial contamination monitoring, Item #4030

lifesignmed.com
4Cultura M Incubator
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Small, durable, reliable incubator for dip paddle incubation, Item #05866

lifesignmed.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Status
Description

Product line brand for rapid immunoassay diagnostic tests including Status COVID-19/Flu A&B, Status Flu, Status Mono, Status Strep A, Status DS (Drugs of Abuse), Status hCG, Status BTA, Status iFOBT, Status RSV, Status H. Pylori, Status Nicotine, and related products.

lifesignmed.com
+4 more records
Core offering1 text field

LifeSign manufactures and distributes rapid point-of-care immunoassay diagnostic test kits across multiple categories including infectious disease (COVID-19/Flu A&B, Strep A, RSV, H. pylori), women's health (hCG), cardiac care (Troponin I, CK-MB, Myoglobin), drugs of abuse, urology (BTA bladder tumor antigen), G.I. health (iFOBT), alcohol and nicotine, industrial microbial monitoring, and surface hygiene testing. Products are CLIA-waived or moderately complex, deliver visual results in 5-15 minutes, and are sold primarily to healthcare providers, clinics, laboratories, industrial customers, and food service operators.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • COVID-19 test: 93.9% sensitivity, 100% specificity
+3 more records
Product overview1 text field

LifeSign is a medical diagnostic company delivering high quality rapid point-of-care testing solutions to the healthcare industry. The product portfolio includes Status™ branded rapid immunoassay tests across multiple categories including infectious disease (COVID-19/Flu A&B, Strep A, RSV, Mono, H. pylori), women's health (hCG pregnancy tests), cardiac care (Troponin I, CK-MB, Myoglobin markers), drugs of abuse (DOA), alcohol and nicotine, G.I. health (iFOBT, H. pylori), urology (BTA, Uricult), hygiene monitoring (Hygicult TPC, Y&F), and industrial applications (Easicult Combi, TTC). Supporting laboratory equipment includes the Cultura® M Incubator. The company also provides associated controls and reagents across product categories.

Product and service21 records
1Status™ COVID-19/Flu A&B
CategoryInfectious Disease
Description

Rapid immunoassay for the simultaneous direct detection and differential diagnosis of SARS-CoV-2, Influenza Type A and Type B antigen. FDA Emergency Use Authorization, visually read in 15 minutes with 93.9% COVID-19 sensitivity, 91.4% Flu A sensitivity, and 87.6% Flu B sensitivity. For clinical use by healthcare providers.

2Status™ Strep A Plus
CategoryInfectious Disease
Description

Rapid immunochromatographic assay for the detection of group A streptococcal antigen directly from throat swab specimens. Simple dip-and-read procedure with results in 5-10 minutes, 96.2% sensitivity and 98.7% specificity.

3Status™ Strep A Strip
CategoryInfectious Disease
Description

Rapid immunochromatographic assay for the detection of group A streptococcal antigen directly from throat swab specimens. CLIA WAIVED with results in 5-10 minutes, 96.2% sensitivity and 98.7% specificity.

4Status™ COVID-19 Antigen Rapid Test For Home Use
CategoryInfectious Disease
Description

Rapid immunoassay for the detection of SARS-CoV-2 antigen for use with anterior nasal swab for at-home use. Visually read results in 15 minutes.

5Status™ RSV
CategoryInfectious Disease
Description

Rapid immuno-chromatographic assay for the qualitative detection of respiratory syncytial virus (RSV) from anterior nasal swab specimens. CLIA waived / 510K cleared with results in 15 minutes.

6Status™ hCG
CategoryWomen's Health
Description

Rapid immunoassay for the detection of human chorionic gonadotropin (hCG) in serum or urine. CLIA WAIVED for urine testing with minimal susceptibility to the hook effect in pregnancy tests.

7Status™ hCG Strip
CategoryWomen's Health
Description

Rapid immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine. CLIA WAIVED with simple dip-and-read procedure, 25 mIU/mL sensitivity, results in 3-5 minutes.

8Status™ H. Pylori
CategoryG.I. Health
Description

Rapid immunoassay for the qualitative detection of anti-helicobacter pylori antibodies in human whole blood, serum or plasma. CLIA WAIVED for whole blood with fingerstick convenience and results in 10 minutes.

9Status™ iFOBT
CategoryG.I. Health
Description

Immunochemical fecal occult blood test for qualitative detection of human hemoglobin in human fecal specimens. CLIA Waived with human hemoglobin specificity to reduce false positives.

10Status™ BTA
CategoryUrology
Description

Rapid test for the qualitative detection of bladder tumor associated antigen in human urine. CLIA WAIVED, indicated as aid in monitoring bladder cancer patients in conjunction with cystoscopy with results in 5 minutes.

11Uricult®
CategoryUrology
Description

Preferred in-office urine culture system. Moderately Complex CLIA category culture method for urinary pathogens with quick and convenient results within 24 hours.

12Status™ DS (Drugs of Abuse)
CategoryDrugs of Abuse (DOA)
Description

One-step immunoassay for the qualitative detection of drugs of abuse and their metabolites in urine. Results in as little as 5 minutes with 97-99% correlation to GC/MS laboratory testing.

13Status™ DS Nicotine
CategoryAlcohol and Nicotine
Description

Rapid immunoassay for the detection of cotinine and nicotine metabolites in urine. Results in 5-10 minutes with 500 ng/mL cut-off to detect active nicotine intake.

14Easicult® Combi
CategoryIndustrial
Description

Dip slides for rapid microbial contamination monitoring in industrial environments such as paint manufacturing, cutting fluids, paper/pulp, and fuel tanks. Contains TTC media for bacteria and Rose-Bengal media for fungi.

15Easicult® TTC
CategoryIndustrial
Description

Dip slides containing TTC agar that allows almost all aerobic bacteria to grow for estimation of total bacterial counts. Helps prevent equipment breakdowns by detecting early signs of corrosion or contamination.

16Hygicult® TPC
CategoryHygiene
Description

Rapid hygiene culture system for monitoring surface hygiene. Supports growth of bacteria, yeasts, and fungi with antidote to neutralize cleaning agents. AOAC approved with hinged dip paddle for testing surfaces, solids or liquids.

17Hygicult® Y&F
CategoryHygiene
Description

Rapid detection of yeast and molds on surfaces using malt agar that supports yeast and mold growth while inhibiting bacteria. For on-site hygiene status testing in schools, hospitals, and food service industries.

18Cultura® M Incubator
CategoryIncubator
Description

Small, durable, reliable incubator suitable for the incubation of dip paddles used in hygiene and industrial testing.

19LifeSign™ MI CK-MB, Myoglobin, Troponin I
CategoryCardiac Care
Description

Rapid qualitative detection of CK-MB, Myoglobin, and Troponin I cardiac markers in human whole blood, serum and plasma to aid in diagnosis of acute myocardial infarction. Combined 3-in-1 test with results in 15 minutes.

20LifeSign™ MI Troponin I
CategoryCardiac Care
Description

Rapid qualitative detection of Troponin I cardiac marker in human whole blood, serum and plasma to aid in diagnosis of acute myocardial infarction. Moderately Complex CLIA category with results in 15 minutes.

21Cardiac Marker Controls
CategoryCardiac Care
Description

External quality controls for monitoring precision of LifeSign™ MI cardiac marker assessment assays. For use with Troponin I, CK-MB, and Myoglobin tests. Lyophilized material with 8-hour reconstituted stability.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-11-22
Description

LifeSign partnered with Major League Table Tennis as a corporate sponsor for the 2025-26 season. This sponsorship includes branding and digital visibility for LifeSign as the league expands to ten teams and secured a national TV deal with CBS Sports.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Response Biomedical develops rapid immunoassay POC tests focused on cardiovascular, infectious disease, and biodefense — overlapping with LifeSign's cardiac marker line (Troponin I, CK-MB, Myoglobin) and operating at a comparable specialty scale.

TypeBroad incumbent
Description

Siemens Healthineers offers the CLINITEST® Rapid COVID-19 Antigen Test and a broader POC diagnostics portfolio, including cardiac markers, competing with LifeSign in clinical settings where integrated lab diagnostics buyers prefer large-vendor solutions.

TypeDirect peer
Description

Sekisui's OSOM® brand of rapid immunoassay tests (Strep A, hCG, Flu, Mono, Trichomonas) is one of the closest direct comparables to LifeSign's Status™ line, with similar product positioning, CLIA-waived portfolio, and physician-office distribution channel.

TypeDirect peer
Description

Trinity Biotech is a specialty diagnostics company offering rapid point-of-care tests (e.g., Uni-Gold HIV, Strep A) and clinical lab products, with comparable mid-sized manufacturing scale and an overlapping POC infectious-disease focus.

TypeBroad incumbent
Description

BD's Diagnostic Systems segment sells the BD Veritor™ system and a portfolio of CLIA-waived rapid tests (Strep A, Flu, RSV, COVID) — overlapping directly with LifeSign's Status™ branded infectious disease and women's health products.

TypeDirect peer
Description

Meridian manufactures rapid diagnostic tests for infectious disease (Strep A, C. difficile, RSV) and other immunoassay kits under its own and partner labels — a similarly sized specialty POC diagnostics company that competes in many of the same clinical categories as LifeSign.

TypeEmerging player
Description

Access Bio manufactures the CareStart™ line of rapid diagnostic tests (COVID-19, Strep A, pregnancy, drugs of abuse) at competitive price points, making it a comparable emerging player in low-cost lateral-flow POC manufacturing.

TypeDirect peer
Description

Princeton BioMeditech develops and manufactures rapid immunochromatographic assays (hCG, Strep A, drugs of abuse) and is publicly listed as a co-sponsor alongside LifeSign for MLTT; it is a direct peer in lateral-flow assay manufacturing and a likely technology partner.

TypeBroad incumbent
Description

QuidelOrtho is a major U.S. diagnostics company with a broad rapid immunoassay portfolio (e.g., Sofia, Triage, QuickVue) spanning infectious disease, cardiac, and women's health — directly competing with LifeSign across most product categories, though at much larger scale and with connected reader platforms.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's rapid diagnostics division (BinaxNOW, ID NOW, Clearview) competes head-to-head with LifeSign in infectious disease and offers CLIA-waived lateral-flow and molecular POC tests, plus a global distribution footprint that dwarfs LifeSign's.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LifeSign

Point-of-Care Diagnosticslifesignmed.com

LifeSign LLC manufactures rapid point-of-care immunoassay diagnostic tests across 10 categories, including infectious disease, cardiac, women's health, urology, and drugs of abuse. Founded 1998 in Skillman, NJ, the privately held firm sells direct to healthcare, industrial, and food service customers.

What LifeSign does

LifeSign LLC is a privately held medical diagnostic company founded in 1998 and headquartered at 85 Orchard Road, Skillman, New Jersey. The company manufactures rapid point-of-care (POC) lateral-flow immunoassay diagnostic tests and serves three core customer segments: healthcare providers (hospitals, clinics, physician offices, laboratories) requiring rapid disease detection and screening, industrial and manufacturing operators needing microbial contamination monitoring (paint, cutting fluids, paper/pulp, fuel tanks), and food service and institutional buyers conducting surface hygiene verification. Product brands include Status™ (rapid immunoassays for infectious disease, cardiac markers, drugs of abuse, women's health, GI health, urology, and alcohol/nicotine testing), Cultura® (incubators), Easicult® (industrial dip slides), Hygicult® (surface hygiene paddles), and Uricult® (in-office urine culture). The portfolio spans 10 product categories sold through direct phone ordering (800-526-2125) and online catalog channels at unit-level pay-as-you-go pricing with no subscription component.

The underlying technology is proprietary rapid immunoassay lateral-flow chemistry delivering visual read-out results typically within 5–15 minutes, with several assays carrying CLIA-waived status for use without complex laboratory infrastructure. Notable technical features include the Status COVID-19/Flu A&B combination assay (FDA Emergency Use Authorization, 93.9%/91.4%/87.6% sensitivity for SARS-CoV-2, Flu A and Flu B), Status MI Troponin I and the 3-in-1 CK-MB/Myoglobin/Troponin I panel for acute myocardial infarction work-up, Status DS drugs-of-abuse assays with 97–99% GC/MS correlation, Status hCG with reduced hook-effect susceptibility, and the Uricult in-office urine culture system (Moderately Complex CLIA, 24-hour culture). Companion hardware includes the Cultura M incubator for dip-paddle workflows. Performance and packaging documentation (package inserts, safety data sheets, sell sheets) are downloadable from the company website.

The commercial model is a focused direct-to-provider B2B motion targeting institutional buyers, with no disclosed distributor or platform dependency, no subscription revenue, and no public listing or external institutional investment. Brand visibility was supplemented in late 2025 via a corporate sponsorship of Major League Table Tennis (announced November 22, 2025) alongside co-sponsors First Advantage and Princeton BioMeditech, coinciding with MLTT's expansion to ten teams and a CBS Sports television deal. The firm operates with 11–50 employees, no disclosed management team, no disclosed certifications or accreditations, and an operating geography skewed to the United States with an aspirational 'global' claim. The broader diagnostic biomarkers market is sized to reach $155.92 billion by 2030 at a 15.5% CAGR, against which LifeSign's current scope is a small, narrowly-scaled participant.

LifeSign firmographics

Firmographics
Name
LifeSign
Legal name
LifeSign LLC
Website
https://lifesignmed.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Short description
LifeSign LLC manufactures rapid point-of-care immunoassay diagnostic tests across 10 categories, including infectious disease, cardiac, women's health, urology, and drugs of abuse. Founded 1998 in Skillman, NJ, the privately held firm sells direct to healthcare, industrial, and food service customers.
Ownership category
akta.pro rank

LifeSign industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Rapid diagnostic tests
  • Point-of-care testing
  • Immunoassay diagnostics
  • Medical diagnostic devices
  • Infectious disease testing

Where LifeSign is headquartered

Location

Headquarters

HQ city
Skillman
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LifeSign business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Point-of-Care Diagnostic Tests: LifeSign generates revenue through the sale of rapid point-of-care diagnostic test kits to healthcare providers. Products include tests for infectious diseases, cardiac markers, drugs of abuse, women's health, GI health, urology, and industrial hygiene applications.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStatus COVID-19/Flu A&B - 1 test device
Unit PricingPay-as-you-goStatus Nicotine - 35 tests
Unit PricingPay-as-you-goEasicult TTC - 10 tests
Unit PricingPay-as-you-goCultura M Incubator

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

LifeSign product offering

Product offering

Core offering

LifeSign manufactures and distributes rapid point-of-care immunoassay diagnostic test kits across multiple categories including infectious disease (COVID-19/Flu A&B, Strep A, RSV, H. pylori), women's health (hCG), cardiac care (Troponin I, CK-MB, Myoglobin), drugs of abuse, urology (BTA bladder tumor antigen), G.I. health (iFOBT), alcohol and nicotine, industrial microbial monitoring, and surface hygiene testing. Products are CLIA-waived or moderately complex, deliver visual results in 5-15 minutes, and are sold primarily to healthcare providers, clinics, laboratories, industrial customers, and food service operators.

Product overview

LifeSign is a medical diagnostic company delivering high quality rapid point-of-care testing solutions to the healthcare industry. The product portfolio includes Status™ branded rapid immunoassay tests across multiple categories including infectious disease (COVID-19/Flu A&B, Strep A, RSV, Mono, H. pylori), women's health (hCG pregnancy tests), cardiac care (Troponin I, CK-MB, Myoglobin markers), drugs of abuse (DOA), alcohol and nicotine, G.I. health (iFOBT, H. pylori), urology (BTA, Uricult), hygiene monitoring (Hygicult TPC, Y&F), and industrial applications (Easicult Combi, TTC). Supporting laboratory equipment includes the Cultura® M Incubator. The company also provides associated controls and reagents across product categories.

Differentiator

Problem solved

Functional benefit

Brands

  • Status: Product line brand for rapid immunoassay diagnostic tests including Status COVID-19/Flu A&B, Status Flu, Status Mono, Status Strep A, Status DS (Drugs of Abuse), Status hCG, Status BTA, Status iFOBT, Status RSV, Status H. Pylori, Status Nicotine, and related products.
  • Cultura
  • Easicult
  • Hygicult
  • Uricult

Products and services

  • Status™ COVID-19/Flu A&B Rapid immunoassay for the simultaneous direct detection and differential diagnosis of SARS-CoV-2, Influenza Type A and Type B antigen. FDA Emergency Use Authorization, visually read in 15 minutes with 93.9% COVID-19 sensitivity, 91.4% Flu A sensitivity, and 87.6% Flu B sensitivity. For clinical use by healthcare providers.
  • Status™ Strep A Plus Rapid immunochromatographic assay for the detection of group A streptococcal antigen directly from throat swab specimens. Simple dip-and-read procedure with results in 5-10 minutes, 96.2% sensitivity and 98.7% specificity.
  • Status™ Strep A Strip Rapid immunochromatographic assay for the detection of group A streptococcal antigen directly from throat swab specimens. CLIA WAIVED with results in 5-10 minutes, 96.2% sensitivity and 98.7% specificity.
  • Status™ COVID-19 Antigen Rapid Test For Home Use Rapid immunoassay for the detection of SARS-CoV-2 antigen for use with anterior nasal swab for at-home use. Visually read results in 15 minutes.
  • Status™ RSV Rapid immuno-chromatographic assay for the qualitative detection of respiratory syncytial virus (RSV) from anterior nasal swab specimens. CLIA waived / 510K cleared with results in 15 minutes.
  • Status™ hCG Rapid immunoassay for the detection of human chorionic gonadotropin (hCG) in serum or urine. CLIA WAIVED for urine testing with minimal susceptibility to the hook effect in pregnancy tests.
  • Status™ hCG Strip Rapid immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine. CLIA WAIVED with simple dip-and-read procedure, 25 mIU/mL sensitivity, results in 3-5 minutes.
  • Status™ H. Pylori Rapid immunoassay for the qualitative detection of anti-helicobacter pylori antibodies in human whole blood, serum or plasma. CLIA WAIVED for whole blood with fingerstick convenience and results in 10 minutes.
  • Status™ iFOBT Immunochemical fecal occult blood test for qualitative detection of human hemoglobin in human fecal specimens. CLIA Waived with human hemoglobin specificity to reduce false positives.
  • Status™ BTA Rapid test for the qualitative detection of bladder tumor associated antigen in human urine. CLIA WAIVED, indicated as aid in monitoring bladder cancer patients in conjunction with cystoscopy with results in 5 minutes.
  • Uricult® Preferred in-office urine culture system. Moderately Complex CLIA category culture method for urinary pathogens with quick and convenient results within 24 hours.
  • Status™ DS (Drugs of Abuse) One-step immunoassay for the qualitative detection of drugs of abuse and their metabolites in urine. Results in as little as 5 minutes with 97-99% correlation to GC/MS laboratory testing.
  • Status™ DS Nicotine Rapid immunoassay for the detection of cotinine and nicotine metabolites in urine. Results in 5-10 minutes with 500 ng/mL cut-off to detect active nicotine intake.
  • Easicult® Combi Dip slides for rapid microbial contamination monitoring in industrial environments such as paint manufacturing, cutting fluids, paper/pulp, and fuel tanks. Contains TTC media for bacteria and Rose-Bengal media for fungi.
  • Easicult® TTC Dip slides containing TTC agar that allows almost all aerobic bacteria to grow for estimation of total bacterial counts. Helps prevent equipment breakdowns by detecting early signs of corrosion or contamination.
  • Hygicult® TPC Rapid hygiene culture system for monitoring surface hygiene. Supports growth of bacteria, yeasts, and fungi with antidote to neutralize cleaning agents. AOAC approved with hinged dip paddle for testing surfaces, solids or liquids.
  • Hygicult® Y&F Rapid detection of yeast and molds on surfaces using malt agar that supports yeast and mold growth while inhibiting bacteria. For on-site hygiene status testing in schools, hospitals, and food service industries.
  • Cultura® M Incubator Small, durable, reliable incubator suitable for the incubation of dip paddles used in hygiene and industrial testing.
  • LifeSign™ MI CK-MB, Myoglobin, Troponin I Rapid qualitative detection of CK-MB, Myoglobin, and Troponin I cardiac markers in human whole blood, serum and plasma to aid in diagnosis of acute myocardial infarction. Combined 3-in-1 test with results in 15 minutes.
  • LifeSign™ MI Troponin I Rapid qualitative detection of Troponin I cardiac marker in human whole blood, serum and plasma to aid in diagnosis of acute myocardial infarction. Moderately Complex CLIA category with results in 15 minutes.
  • Cardiac Marker Controls External quality controls for monitoring precision of LifeSign™ MI cardiac marker assessment assays. For use with Troponin I, CK-MB, and Myoglobin tests. Lyophilized material with 8-hour reconstituted stability.

Quantifiable outcome

  • COVID-19 test: 93.9% sensitivity, 100% specificity
  • +3 more outcomes

Companies that use LifeSign

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

LifeSign technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

LifeSign partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Major League Table Tennis (MLTT)minorGTM or Marketing Partner · 22 November 2025LifeSign partnered with Major League Table Tennis as a corporate sponsor for the 2025-26 season. This sponsorship includes branding and digital visibility for LifeSign as the league expands to ten teams and secured a national TV deal with CBS Sports.

Scale indicators2 records

Recent moves2 records

Expansion highlights4 records

LifeSign competitors and assessment

Company assessment

Emerging players

  • Response Biomedical: Response Biomedical develops rapid immunoassay POC tests focused on cardiovascular, infectious disease, and biodefense — overlapping with LifeSign's cardiac marker line (Troponin I, CK-MB, Myoglobin) and operating at a comparable specialty scale.
  • Access Bio (CareStart): Access Bio manufactures the CareStart™ line of rapid diagnostic tests (COVID-19, Strep A, pregnancy, drugs of abuse) at competitive price points, making it a comparable emerging player in low-cost lateral-flow POC manufacturing.

Broad incumbents

  • Siemens Healthineers (Rapid Diagnostics): Siemens Healthineers offers the CLINITEST® Rapid COVID-19 Antigen Test and a broader POC diagnostics portfolio, including cardiac markers, competing with LifeSign in clinical settings where integrated lab diagnostics buyers prefer large-vendor solutions.
  • Becton Dickinson (BD): BD's Diagnostic Systems segment sells the BD Veritor™ system and a portfolio of CLIA-waived rapid tests (Strep A, Flu, RSV, COVID) — overlapping directly with LifeSign's Status™ branded infectious disease and women's health products.
  • QuidelOrtho: QuidelOrtho is a major U.S. diagnostics company with a broad rapid immunoassay portfolio (e.g., Sofia, Triage, QuickVue) spanning infectious disease, cardiac, and women's health — directly competing with LifeSign across most product categories, though at much larger scale and with connected reader platforms.
  • Abbott Diagnostics: Abbott's rapid diagnostics division (BinaxNOW, ID NOW, Clearview) competes head-to-head with LifeSign in infectious disease and offers CLIA-waived lateral-flow and molecular POC tests, plus a global distribution footprint that dwarfs LifeSign's.

Direct peers

  • Sekisui Diagnostics (OSOM): Sekisui's OSOM® brand of rapid immunoassay tests (Strep A, hCG, Flu, Mono, Trichomonas) is one of the closest direct comparables to LifeSign's Status™ line, with similar product positioning, CLIA-waived portfolio, and physician-office distribution channel.
  • Trinity Biotech: Trinity Biotech is a specialty diagnostics company offering rapid point-of-care tests (e.g., Uni-Gold HIV, Strep A) and clinical lab products, with comparable mid-sized manufacturing scale and an overlapping POC infectious-disease focus.
  • Meridian Bioscience: Meridian manufactures rapid diagnostic tests for infectious disease (Strep A, C. difficile, RSV) and other immunoassay kits under its own and partner labels — a similarly sized specialty POC diagnostics company that competes in many of the same clinical categories as LifeSign.
  • Princeton BioMeditech: Princeton BioMeditech develops and manufactures rapid immunochromatographic assays (hCG, Strep A, drugs of abuse) and is publicly listed as a co-sponsor alongside LifeSign for MLTT; it is a direct peer in lateral-flow assay manufacturing and a likely technology partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

LifeSign social profiles

Digital presence

LifeSign financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LifeSign leadership team

Management profile

Number of profiles

LifeSign funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LifeSign M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeSign

What does LifeSign do?

LifeSign manufactures and distributes rapid point-of-care immunoassay diagnostic test kits across multiple categories including infectious disease (COVID-19/Flu A&B, Strep A, RSV, H. pylori), women's health (hCG), cardiac care (Troponin I, CK-MB, Myoglobin), drugs of abuse, urology (BTA bladder tumor antigen), G.I. health (iFOBT), alcohol and nicotine, industrial microbial monitoring, and surface hygiene testing. Products are CLIA-waived or moderately complex, deliver visual results in 5-15 minutes, and are sold primarily to healthcare providers, clinics, laboratories, industrial customers, and food service operators.

Is LifeSign a public or private company?

LifeSign is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was LifeSign founded?

LifeSign was founded in 1998. It employs 11 to 50 people.

Where is LifeSign based?

LifeSign is headquartered in Skillman, United States, in the North America region.

How does LifeSign make money?

One revenue line is on record: point-of-Care Diagnostic Tests.

Who are LifeSign's main competitors?

Emerging players on record are Response Biomedical and Access Bio (CareStart). Broad incumbents are Siemens Healthineers (Rapid Diagnostics), Becton Dickinson (BD), QuidelOrtho and Abbott Diagnostics. Direct peers are Sekisui Diagnostics (OSOM), Trinity Biotech, Meridian Bioscience and Princeton BioMeditech.

Does LifeSign have an API?

No public API is recorded for LifeSign.

What industry is LifeSign in?

LifeSign's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals